Author:
Bombardieri E.,Alessi A.,Villano C.,Gerali A.,Crippa F.
Publisher
Springer Berlin Heidelberg
Reference248 articles.
1. Adams S, Baum RP, Rink T, Schumm-Drager PM, Usadel KH, Hoh G (1998a) Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25:79–83
2. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G (1998b) Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25:1255–1260
3. Adler LP, Bakale G (2001) Positron emission tomography imaging. In: Khalkhali I, Maublant JC, Goldsmith SJ (eds) Nuclear oncology. Diagnosis and therapy. Lippincott, Williams & Wilkins, Philadelphia, pp 289–295
4. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR (1997) Axillary lymph node metastases: screening with (F-18)2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 203: 323–327
5. Ahlstrom H, Eriksson B, Bergstrom M, Bjurling P, Langstrom B, Oberg K (1995) Pancreatic neuroendocrine tumors: Diagnosis with PET. Radiology 195:333–337